BrainTrip brings brain diagnostics to the point of care by breathing new life into an old technology.

Dementia represents one of the most urgent healthcare challenges of our time, with 75% of cases going undiagnosed, leaving millions without access to timely interventions.

Early detection is vital, especially as emerging treatments are only effective in the earliest stages.

With 2 billion people globally at risk and a potential market exceeding $2.8 trillion by 2030, BrainTrip is positioned to seize a significant share of this growing market with CogniScore.

CogniScore, part of their proprietary NeuroAI operating system, provides a groundbreaking approach to addressing this unmet need.

CleanShot 2024-11-21 at 12.59.30@2x.png

Here's how CogniScore is disrupting dementia care:

Why BrainTrip?

Fundraising Ask:

BrainTrip is raising a €1M seed round, with €500k already secured from a strategic partner, to accelerate market expansion.

Call to Action: